<DOC>
	<DOCNO>NCT00617344</DOCNO>
	<brief_summary>This follow study use three different formulation serotype aim test immunogenicity reactogenicity Primary Objective : Immunogenicity : To evaluate immunogenicity neutralize antibody response post dose 2 . Secondary Objectives : Safety : To evaluate safety follow three formulation ChimeriVax™ Tetravalent Dengue Vaccine . Immunogenicity : To describe neutralize antibody response dose .</brief_summary>
	<brief_title>Immunogenicity Safety Three Formulations Dengue Vaccines Healthy Adults Aged 18 45 Years US</brief_title>
	<detailed_description>This phase II , double-blind , randomize , descriptive , multicenter study US adult subject . Subjects randomize receive total three dos ChimeriVax™ Tetravalent Dengue Vaccine one particular formulation .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , determine medical history , clinical examination , biological safety parameter . Aged 18 45 year day inclusion . Provision inform consent sign subject another legally acceptable representative . For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination , least 4 week last study vaccination . Able attend schedule visit comply trial procedure . Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia . For woman childbearing potential , know suspected pregnancy positive serum/urine pregnancy test . Breastfeeding woman . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm ( least 2 week within previous 3 month ) systemic corticosteroid therapy ( dose least 10 mg ) . Topical steroid allow . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion , opinion investigator . Current past alcohol abuse drug addiction may interfere subject 's ability comply trial procedure . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow trial vaccination . Human Immunodeficiency Virus ( HIV ) , hepatitis B surface antigen , hepatitis C seropositivity blood sample take Screening . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Clinically significant laboratory test abnormality ( determined investigator ) blood sample take Screening . Previous residence , travel plan travel 2 week study period area high dengue infection endemicity . ( Please refer Appendix 5 protocol . ) Reported history flavivirus infection report subject . Previous vaccination flavivirus disease ( include Japanese encephalitis , tickborne encephalitis , yellow fever ) Flavivirus vaccination plan trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue virus</keyword>
</DOC>